Prognostic value of progesterone receptor expression in tubo‐ovarian high‐grade serous carcinoma of the COEUR cohort

The association between progesterone receptor (PR) expression and improved outcome of ovarian cancer patients has been reported with conflicting results (1). To clarify the prognostic role of PR expression patients, Luo et al. (1) performed a meta-analysis of 28 published studies. The authors found that PR expression detected by immunohistochemistry (IHC) was associated with favorable overall survival (hazard ratio [HR] = 0.86) combining studies not stratified by histotypes. This article is protected by copyright. All rights reserved.

[1]  C. Le Page,et al.  Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers , 2018, BMC Cancer.

[2]  Xueqiong Zhu,et al.  Prognostic value of progesterone receptor expression in ovarian cancer: a meta-analysis , 2017, Oncotarget.

[3]  M. Köbel,et al.  Association of Hormone Receptor Expression with Survival in Ovarian Endometrioid Carcinoma: Biological Validation and Clinical Implications , 2017, International journal of molecular sciences.

[4]  M. Köbel,et al.  Molecular alterations in indolent, aggressive and recurrent ovarian low‐grade serous carcinoma , 2017, Histopathology.

[5]  S. Leung,et al.  An Immunohistochemical Algorithm for Ovarian Carcinoma Typing , 2016, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[6]  R. Labianca,et al.  Assessment of a HER2 scoring system for colorectal cancer: results from a validation study , 2015, Modern Pathology.

[7]  A. Whittemore,et al.  Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. , 2013, The Lancet. Oncology.

[8]  I. Ellis,et al.  Investigating AP-2 and YY1 protein expression as a cause of high HER2 gene transcription in breast cancers with discordant HER2 gene amplification , 2009, Breast Cancer Research.

[9]  L. Goldstein,et al.  High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system , 2008, Modern Pathology.

[10]  C. Sotiriou,et al.  Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily Practice , 2005, Clinical Cancer Research.